| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Over the last 12 months, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of ABVC BioPharma, Inc. stock.
On average, over the past 5 years, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $1,500 was made by Nirta Joseph (director) on 2010‑05‑11.
| 2010-05-11 | Nirta Joseph | director | 10,000 0.0305% | $0.15 | $1,500 | |||
| 2010-03-22 | Nirta Joseph | director | 2,000 0.0061% | $0.26 | $520 | |||
| 2009-10-01 | Stromback Richard Dean | 10 percent owner | 240 – | $0.42 | $101 | |||
| 2009-04-14 | Smith J.B. | 21 <0.0001% | $0.75 | $16 | ||||
| 2009-01-23 | Sale | Stromback Richard Dean | 4M 13.8448% | $1.00 | $4M | |||
| 2009-01-23 | Smith J.B. | 4M 13.8448% | $1.00 | $4M | ||||
| 2008-08-18 | Sale | Stromback Richard Dean | CEO | 1.5M 0.3123% | $1.00 | $1.5M | ||
| 2007-07-30 | Ramsey Sally Judith | VP New Product Development | 3M – | $0 | $0 |
| Increased Positions | 10 | +100% | 103,781 | +13.21% |
| Decreased Positions | 4 | -40% | 34,205 | -4.36% |
| New Positions | 2 | New | 16,042 | New |
| Sold Out Positions | 2 | Sold Out | 19,753 | Sold Out |
| Total Postitions | 16 | +60% | 854,906 | +8.86% |
| Vanguard Group Inc | $586.00 | 1.11% | 267,450 | +155,917 | +139.79% | 2025-09-30 |
| Geode Capital Management, Llc | $411.00 | 0.78% | 187,812 | +77,313 | +69.97% | 2025-09-30 |
| Renaissance Technologies Llc | $242.00 | 0.46% | 110,500 | +68,794 | +164.95% | 2025-09-30 |
| State Street Corp | $159.00 | 0.3% | 72,800 | +59,900 | +464.34% | 2025-09-30 |
| Blackrock, Inc. | $124.00 | 0.24% | 56,442 | +56,442 | New | 2025-09-30 |
| Northern Trust Corp | $54.00 | 0.1% | 24,821 | -12,323 | -33.18% | 2025-09-30 |
| Xtx Topco Ltd | $54.00 | 0.1% | 24,801 | -27,824 | -52.87% | 2025-09-30 |
| Millennium Management Llc | $43.00 | 0.08% | 19,603 | +19,603 | New | 2025-09-30 |
| Citadel Advisors Llc | $34.00 | 0.07% | 15,664 | +15,664 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $5.00 | 0.01% | 2,155 | +1,801 | +508.76% | 2025-09-30 |